Page 3 - Dr Reddys

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Dr Reddy's extends fall on disappointing Q1; stock down 14% in 2 days

The stock of the pharmaceutical company was trading at its lowest level since April 9, 2021

Five Indian drugmakers to jointly start trial of Merck & Co's Covid-19 drug

(Reuters) - Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

Dr Reddy's Laboratories announces commercial launch of Covid-19 drug 2-DG

: Dr. Reddy's Laboratories Ltd on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG). According to a press release issued by the city-based drug maker, Dr. Reddy's will supply the drug to major government as well as private hospitals across India. In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of the country. 2-DG manufactured by Dr. Reddy's has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidized rate offered to Government institutions, it said. 2-DG, a oral drug was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's. Dr. G Satheesh Reddy, Secretary, Department of Defence (R&D) and Chairman, DRDO

Nomura remains overweight on India; Infosys, RIL, ICICI Bank among top bets

Going ahead, Nomura said, markets will focus more on corporate earnings rather than the broad economic growth in India

We have sole selling rights, beware of fake agents of Sputnik-V: Dr Reddy's

Hyderabad-based pharma major says it isn't supplying Russia jab to residential societies

DRDO's 2DG anti-Covid drug priced at Rs 990 per sachet: Dr Reddy's

The drug will be provided to government hospitals at a discounted price, ANI quoted government officials as saying.

Dr Reddy's in talks with RDIF to sell Sputnik V in other countries

Dr Reddys Laboratories is in a pact with Russian Direct Investment Fund to sell 250 million vials of Covid-19 vaccine Sputnik V in India

Stocks to watch: L&T, DRL, UPL, Eicher Motors, Happiest Minds, Tata Power

Royal Enfield said it has decided to shut down its two manufacturing facilities between May 13-16 amid a second Covid wave

Lilly signs 3 pacts to expand availability of baricitinib for Covid patient

Eli Lilly has issued additional royalty-free, non-exclusive voluntary licenses to Dr Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals

Sun Pharma, Dr Reddy's, Aurobindo recall products in the US market

Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma and Jubilant Pharma are recalling products in the US market, the world's largest market for pharmaceutical products, for various reasons

Bull Spread strategy on Dr Reddy's Labs by Nandish Shah of HDFC Securities

The stock price has broken out on the daily chart where it closed above 200-day EMA with higher volumes

Stocks to watch: Nureca, Max Fin, Axis Bank, DRL, Dredging Corp, Affle

Wipro announced the appointment of Rene Mulder as Country Head and Managing Director of its Switzerland operations

Dr Reddy's launches stomach, esophagus problems treatment drug in US

The product is a therapeutic equivalent generic version of Prevacid SoluTab delayed release orally disintegrating tablets approved by the US Food and Drug Administration (USFDA)

Dr Reddy's Laboratories launches cancer treatment drug Capecitabine in US

The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA)

Dr Reddys falls 10% in 2 days, hits over 4-month low post Q3 results

The company said the profits were impacted due to trigger based impairment charge taken on a few acquired products including gNuvaring

Dr Reddy's posts Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 20 crore for the October to December quarter as against a consolidated net loss of Rs 570 crore in the year-ago period.Not accounting for impairment cost, the company's net profit in the quarter would have been at Rs 882 crore, it said.The company's consolidated revenues grew 12 per cent year-on-year to Rs 4,930 crore.There were significant changes to the market conditions for certain of the products fanning part of company's global generics and proprietary products segments, said the company."We continued with our growth momentum while maintaining EBITDA margins. We are progressing well on phase three clinical trials for Sputnik V vaccine in India," said Co-Chairman and Managing Director G V Prasad.The company's revenues in India increased by 26 per cent year-on-year to Rs 959 crore in Q3 FY21. In North America, the sales rose 9 per cent to Rs 1,739 crore.

Dr Reddy's to acquire select brands from Glenmark in Russia, Ukraine

Dr Reddy's Laboratories on Saturday said it had inked a pact with Glenmark Pharmaceuticals to acquire its select anti-allergy brands in Russia, Ukraine, Kazakhstan and Uzbekistan

Weekly stock picks by Religare Broking: Buy Aurobindo Pharma, Marico

The chart pattern and positioning of oscillators are pointing towards a sharp up move in Aurobindo Pharma in the near future

A brief history of Indian companies' tryst with class action suits

Companies ranging from IT to pharmaceuticals have been dragged to courts